When developing vaccines, functional feeds, therapeutics, or selective breeding programs, the challenge model you choose can significantly influence your results. In this article, we explore why different Infectious Pancreatic Necrosis Virus (IPNV) isolates produce different disease outcomes—and why testing against the right strain is essential for generating meaningful efficacy data. Learn how Onda's unique access to Chilean, Scottish, and Norwegian IPNV isolates helps clients develop products with greater confidence for their target markets.